Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinge Zhao

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Cancer Treatment Reviews|June 21, 2024
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysisYaowen Zhang, Junru Chen, Haoyang Liu, et al.
Cancer Management and Research|September 13, 2021
Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell CarcinomaXudong Zhu, Xingming Zhang, Guangxi Sun, et al.
American Journal of Translational Research|October 12, 2020
Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinomaXiaoxue Yin, Xingming Zhang, Zhenhua Liu, et al.
BMC Cancer|April 18, 2019
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinomaXingming Zhang, Xiaoxue Yin, Haoran Zhang, et al.
The Prostate|March 4, 2025
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone AcetateYifu Shi, Xinyuan Wei, Fengnian Zhao, et al.
Cancer Medicine|July 28, 2021
Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abirateroneSha Zhu, Yuchao Ni, Guangxi Sun, et al.
The Journal of Pathology. Clinical Research|April 2, 2025
Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinomaQiyu Zhu, Ting Wang, Yifu Shi, et al.
Frontiers in Pharmacology|February 4, 2022
Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysisJunru Chen, Yaowen Zhang, Xingming Zhang, et al.
The Prostate|October 28, 2024
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patientsXinyuan Wei, Jinge Zhao, Ling Nie, et al.
Asian Journal of Andrology|August 30, 2016
Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancerGuang-Xi Sun, Peng-Fei Shen, Xing-Ming Zhang, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Cancer Treatment Reviews|June 21, 2024
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysisYaowen Zhang, Junru Chen, Haoyang Liu, et al.
Cancer Management and Research|September 13, 2021
Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell CarcinomaXudong Zhu, Xingming Zhang, Guangxi Sun, et al.
American Journal of Translational Research|October 12, 2020
Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinomaXiaoxue Yin, Xingming Zhang, Zhenhua Liu, et al.
BMC Cancer|April 18, 2019
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinomaXingming Zhang, Xiaoxue Yin, Haoran Zhang, et al.
The Prostate|March 4, 2025
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone AcetateYifu Shi, Xinyuan Wei, Fengnian Zhao, et al.
Cancer Medicine|July 28, 2021
Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abirateroneSha Zhu, Yuchao Ni, Guangxi Sun, et al.
The Journal of Pathology. Clinical Research|April 2, 2025
Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinomaQiyu Zhu, Ting Wang, Yifu Shi, et al.
Frontiers in Pharmacology|February 4, 2022
Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysisJunru Chen, Yaowen Zhang, Xingming Zhang, et al.
The Prostate|October 28, 2024
Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patientsXinyuan Wei, Jinge Zhao, Ling Nie, et al.
Asian Journal of Andrology|August 30, 2016
Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancerGuang-Xi Sun, Peng-Fei Shen, Xing-Ming Zhang, et al.
Pageof 10